J A DiMasi

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi The price of innovation: new estimates of drug development costs
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, MA 02111, USA
    J Health Econ 22:151-85. 2003
  2. ncbi Emerging role of pharmacoeconomics in the research and development decision-making process
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, 02111, USA
    Pharmacoeconomics 19:753-66. 2001
  3. ncbi Economics of new oncology drug development
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    J Clin Oncol 25:209-16. 2007
  4. doi Trends in risks associated with new drug development: success rates for investigational drugs
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 87:272-7. 2010
  5. doi Clinical approval success rates for investigational cancer drugs
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 94:329-35. 2013
  6. doi Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts 02111, USA
    Clin Ther 35:808-18. 2013
  7. ncbi The economics of follow-on drug research and development: trends in entry rates and the timing of development
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 22:1-14. 2004
  8. doi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:183-8. 2011
  9. ncbi Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts
    Christopher Paul Milne
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Am J Ther 14:231-4. 2007
  10. ncbi The value of improving the productivity of the drug development process: faster times and better decisions
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Pharmacoeconomics 20:1-10. 2002

Detail Information

Publications14

  1. ncbi The price of innovation: new estimates of drug development costs
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, MA 02111, USA
    J Health Econ 22:151-85. 2003
    ..When compared to the results of an earlier study with a similar methodology, total capitalized costs were shown to have increased at an annual rate of 7.4% above general price inflation...
  2. ncbi Emerging role of pharmacoeconomics in the research and development decision-making process
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, 02111, USA
    Pharmacoeconomics 19:753-66. 2001
    ....
  3. ncbi Economics of new oncology drug development
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    J Clin Oncol 25:209-16. 2007
    ..Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development...
  4. doi Trends in risks associated with new drug development: success rates for investigational drugs
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 87:272-7. 2010
    ..The estimated transition probabilities were also higher for all clinical phases with respect to large molecules...
  5. doi Clinical approval success rates for investigational cancer drugs
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 94:329-35. 2013
    ..9 and 42.4%, respectively, for second and third indications if the first indication is a success, but 2.5 and 1.8%, respectively, if the first indication is a failure)...
  6. doi Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts 02111, USA
    Clin Ther 35:808-18. 2013
    ..Little attention has been paid to new uses for already-approved compounds, which can be an important form of innovation...
  7. ncbi The economics of follow-on drug research and development: trends in entry rates and the timing of development
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 22:1-14. 2004
    ..This study examines data on the trends in the speed with which competitive entry has occurred in the pharmaceutical marketplace and the competitive nature of the industry's development of these drugs...
  8. doi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:183-8. 2011
    ..1 and 6.9 years, respectively). The results provide the underpinnings of a fundamental shift in the structure of the research-based industry...
  9. ncbi Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts
    Christopher Paul Milne
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Am J Ther 14:231-4. 2007
  10. ncbi The value of improving the productivity of the drug development process: faster times and better decisions
    Joseph A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Pharmacoeconomics 20:1-10. 2002
    ..The effect on drug development costs from faster development, earlier decisions on project failures, and higher approval success rates are quantified...
  11. ncbi Should the patent system for new medicines be abolished?
    J A DiMasi
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 82:488-90. 2007
  12. ncbi Returns on research and development for 1990s new drug introductions
    Henry Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Pharmacoeconomics 20:11-29. 2002
    ....
  13. ncbi What's time got to do with it?
    Joseph A DiMasi
    Health Aff (Millwood) 25:1188; author reply 1188. 2006
  14. doi Misleading congress about drug development: Reply
    Joseph A DiMasi
    Tufts University
    J Health Polit Policy Law 33:319-24; discussion 325-7. 2008
    ....